Author: Su, Yen-Bo; Kuo, Ming-Jen; Lin, Ting-Yu; Chien, Chian-Shiu; Yang, Yi-Ping; Chou, Shih-Jie; Leu, Hsin-Bang
Title: Cardiovascular manifestation and treatment in COVID-19 Cord-id: j82q99in Document date: 2020_5_19
ID: j82q99in
Snippet: The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiom
Document: The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. Many studies have published timely to help global healthcare workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (eg, hypertension, coronary disease, or cardiomyopathy), diabetes, and chronic kidney disease have worse outcomes after COVID-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias, or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here, we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.
Search related documents:
Co phrase search for related documents- acceptable safety and acute ards: 1
- acceptable safety and acute ards respiratory distress syndrome: 1
- acceptable safety and acute kidney injury: 1
- acceptable safety and acute respiratory infection: 1
- acceptable safety and adhesion molecule: 1
- acceptable safety and lopinavir ritonavir: 1, 2
- acceptable safety and low mortality: 1
- acceptable safety and magnetic resonance: 1, 2
- ace inhibitor and action mechanism: 1, 2, 3, 4
- ace inhibitor and acute ards: 1, 2, 3, 4
- ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
- ace inhibitor and acute coronary syndrome: 1
- ace inhibitor and acute kidney injury: 1, 2, 3, 4
- ace inhibitor and acute lung injury: 1, 2, 3, 4
- ace inhibitor and acute myocardial infarction: 1, 2
- ace inhibitor and acute respiratory infection: 1, 2, 3, 4
- ace inhibitor and low molecular weight heparin: 1
- ace inhibitor and lung injury: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date